Human immunodeficiency virus (HIV) remains a persistent public health concern throughout
the world. Substance use disorders (SUDs) are a common comorbidity that can worsen …

The fronto-striatal circuitry, involving the nucleus accumbens, ventral tegmental area, and
prefrontal cortex, mediates goal-directed behavior and is targeted by both drugs of abuse …

The marked increase in life expectancy for HIV-1 seropositive individuals, following the great
success of combination antiretroviral therapy (cART), heralds an examination of the …

The persistence of HIV-1 viral reservoirs in the brain, despite treatment with combination
antiretroviral therapy (cART), remains a critical roadblock for the development of a novel …

Abstract Between 30 and 60% of HIV-seropositive individuals develop symptoms of clinical
depression and/or apathy. Dopamine and serotonin are associated with motivational …

While current therapeutic strategies for people living with human immunodeficiency virus
type 1 (HIV-1) suppress virus replication peripherally, viral proteins such as transactivator of …

Our previous findings demonstrated that astrocytic HIF‐1α plays a major role in HIV‐1 Tat‐
mediated amyloidosis which can lead to Alzheimer's‐like pathology‐a comorbidity of HIV …

Varying degrees of cognitive deficits affect over half of all HIV-1 infected patients. Because of
antiretroviral treatment (ART) regimens, the HIV-1 patient population is increasing in age …

Central nervous system involvement in HIV infection leads to neurobehavioural sequelae.
Although apathy is a well-recognised symptom in adults living with HIV linked to alterations …

Background Human immunodeficiency virus (HIV) affects nearly 40 million people globally,
with roughly 80% of all people living with HIV receiving antiretroviral therapy. Antiretroviral …